Skip to main content
SpringerLink
Log in

Phase II study of ionidamine in patients with metastatic breast cancer

An Eastern Cooperative Oncology Group study

  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silvestrini B, Band PR, Caputo A, Young CW (eds): Lonidamine. Proc Second Int Symp Oncol 41 (suppl 1):1‐123, 1984

  2. Oken MH, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–665, 1982

    CAS  PubMed  Google Scholar 

  3. Band PR, Maroun J, Pritchard K, Stewart D, Coppin CM, Wilson K, Eisenhauer EA: Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 70:1305–1310, 1986

    Google Scholar 

  4. Pronzato P, Gulisano M, Amoroso D, Ardizzoni A, Biruzzone M, Conte PF, Rosso R, Ciottoli GB: Lonidamine in breast cancer. A Phase II study. EORTC Breast Cancer Symposium, Abstract 4179, 1987

  5. Lionetto R, Pronzato P, Cusimano MP, Gulisano M, Amoroso D, Bertelli G, Conte PF, Rosso R: Phase II trial of lonidamine in advanced breast cancer. Proc Am Soc Clin Oncol 7:20, 1988

    Google Scholar 

  6. Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B, Caputo A: In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Research 6:1245–1250, 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, Harvard School of Public Health, CA-23318, Boston, MA, USA

    Donna S. Neuberg

  2. Northwestern University Medical Center, Chicago, IL, USA

    Al B. Benson III

  3. University of Rochester Cancer Center, Rochester, NY, USA

    Kishan J. Pandya

  4. St. Mary's Hospital CCOP, USA

    Kishan J. Pandya

  5. University of Wisconsin Clinical Cancer Center, 600 Highland Avenue, 53792, Madison, WI, USA

    H. Ian Robins & Douglass C. Tormey

Authors
  1. H. Ian Robins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donna S. Neuberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Al B. Benson III
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kishan J. Pandya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Douglass C. Tormey
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Other participating institutions include: Fox Chase Cancer Center, Philadelphia, PA (CA-18281); Medical College of Ohio, Toledo, OH; Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL (CA-25988), Evanston Hospital (CCOP), Evanston, IL.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robins, H.I., Neuberg, D.S., Benson, A.B. et al. Phase II study of ionidamine in patients with metastatic breast cancer. Invest New Drugs 8, 397–399 (1990). https://doi.org/10.1007/BF00198600

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00198600

Key words

Search

Navigation